Smart Cancer Guide

1. Core similarity: same drug, different strategy Both programs use: Pembrolizumab (anti–PD-1 immunotherapy) In MSI-high / dMMR colorectal cancer Aiming to harness immune system tumor control But they differ in a crucial way: KEYNOTE = mostly advanced/metastatic or adjuvant settings NEOPRISM = true neoadjuvant “pre-surgery immune priming” strategy. 2. KEYNOTE colorectal program (what it established) 🔹 KEYNOTE-177 (landmark trial) KEYNOTE-177 Trial Population: Metastatic MSI-high / dMMR colorectal cancer Design: Pembrolizumab vs chemotherapy Key results: Progression-free survival: ~16 vs ~8 months Higher response durability Lower toxicity than chemo Key limitation: Majority of patients still have disease progression over time Not designed for “curative intent” 👉 Bottom line: KEYNOTE-177 established pembrolizumab as first-line metastatic standard , not a cure strategy. 🔹 KEYNOTE-016 / 164 / 158 (earlier proof-of-concept) KEYNOTE-016 Trial Showed high response rates (~30–40%+ durable r...

Quick Summary Genetics = study of individual genes , often inherited → cancer risk Genomics = study of the entire genome → tumor biology Biomarkers = actionable indicators → treatment decisions 👉 Simple model: Genetics → Risk | Genomics → Understanding | Biomarkers → Action Why This Matters in Modern Oncology Cancer care has shifted from: “Where is the tumor?” to “What is driving the tumor at a molecular level?” To answer that, oncology now integrates: Genetics (inherited risk) Genomics (tumor-wide mutations) Biomarkers (clinical decision tools) Together, they form the foundation of precision oncology . 1. Genetics: The Inherited Blueprint Genetics focuses on single genes and inherited mutations (germline DNA). What it tells you: Who is at higher risk of cancer Why cancer runs in families Examples: BRCA1 / BRCA2 → breast & ovarian cancer Lynch syndrome genes → colorectal cancer Clinical use: Screening and prevention Family risk assessment 👉 Genetics answers: “Am I at risk o...

Executive Summary Over the past several years, repurposed antiparasitic drugs—particularly fenbendazole , mebendazole , and ivermectin —have attracted widespread attention in oncology communities. A publicly accessible compilation hosted by OneDayMD documents more than 700 anecdotal cancer cases reporting tumor regression, stabilization, or remission while using these agents, often in combination with conventional therapy or adjunctive supplements. This report does not treat these anecdotes as proof of efficacy. Instead, it applies pharmacovigilance logic, bias analysis, mechanistic plausibility review, and comparative survival context to assess whether this body of reports constitutes: Noise Wishful thinking Or a legitimate hypothesis-generating signal Conclusion: The dataset does not constitute mainstream clinical evidence. However, the signal density, mechanistic plausibility, and cross-cancer recurrence pattern justify formal prospective evaluation under controlled conditions. 1. ...

GLP-1 receptor agonists such as Semaglutide and Tirzepatide have transformed the treatment of obesity and type 2 diabetes. As their use expands globally, a critical question is emerging: Do GLP-1 drugs reduce cancer risk — or is any apparent benefit simply a consequence of weight loss and improved metabolic health? This article reviews: The established link between obesity and cancer The biological mechanisms affected by GLP-1 therapy Human clinical trial data Observational cancer incidence studies Safety signals (including thyroid cancer) What remains unknown All claims below are supported by peer-reviewed sources. 1. Obesity and Cancer: Established Evidence The link between obesity and cancer is well established. The International Agency for Research on Cancer concluded in 2016 that excess body fat increases the risk of at least 13 cancers (1). Key cancers linked to obesity include: Colorectal Postmenopausal breast Endometrial Pancreatic Liver Mechanisms supported by human and transl...

Disclaimer: Educational content only. Not medical advice. No therapy listed is a cure for cancer. 1. Introduction Cancer care is no longer a single-path system. Modern oncology integrates tumor biology, genetics, metabolism, and supportive care. However, online information is often split between medical websites and alternative health blogs, creating confusion. Most cancer treatment pages—including major medical institutions—focus on just listing available 'alternative' cancer therapies (e.g. 'Alternative cancer treatments: 11 options to consider' - by Mayo Clinic ). Despite the title “Alternative cancer treatments,” the article is not about cancer cures or alternative oncology systems . It is actually a s upportive care guide (integrative oncology overview disguised as “alternative treatments”). Many patients explore “alternative cancer treatments” hoping for additional options. However, this area is often misunderstood, misrepresented, and sometimes exploited by mi...

Cancer treatment in 2026 is no longer about choosing one therapy—it’s about choosing the right combination based on tumor biology, stage, and patient factors . The three foundational approaches remain: Immunotherapy (activates the immune system) Chemotherapy (kills rapidly dividing cells) Radiotherapy (targets tumors locally with radiation) Each has unique strengths, limitations, survival outcomes, and cost implications . Credit:  Statista Immunotherapy (Immune-Based Cancer Treatment) Immunotherapy works by helping your immune system recognize and destroy cancer cells more effectively . Common drugs include: Pembrolizumab Nivolumab Ipilimumab How Immunotherapy Works Blocks immune checkpoints (PD-1, PD-L1, CTLA-4) Reactivates T-cells to attack tumors Enhances immune recognition of cancer Survival Rates and Outcomes Melanoma: 5-year survival increased to ~50% or higher in responders Lung cancer (PD-L1 high): Significantly longer survival vs chemotherapy alone MSI-high cancers: So...

Introduction: The Science of Metabolic Therapy in Cancer Cancer research is undergoing a paradigm shift—from a predominantly genetic view of disease toward a more integrated understanding that includes cellular metabolism as a central driver of tumor growth. Over the past decade, advances in cancer biology have revealed that malignant cells are not only genetically altered but also metabolically reprogrammed to sustain rapid proliferation, resist cell death, and adapt to hostile microenvironments. ( SpringerLink ) At its core, metabolic therapy for cancer is based on the principle that tumor cells exhibit distinct metabolic behaviors compared to normal cells. One of the most well-known examples is the Warburg effect , where cancer cells preferentially utilize aerobic glycolysis—consuming large amounts of glucose and producing lactate even in the presence of oxygen. This inefficient yet rapid energy-generating pathway supports biosynthesis, redox balance, and cellular growth, providi...